Barr Laboratory BRL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Barr Laboratory BRL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: harkenman who wrote (82)	10/26/1997 7:54:00 PM
From: hb	Read Replies (1) of 207

While MYL is expected to earn 5-6cents higher than expected due to generic version of drug (zantac like)used for stomach ulcer and acidity, this may not continue for ever. There is an alternative antibiotic treatment that is permanant cure in nature in contrast to the temporary nature of zantac.(i consider usage of zantac like drugs without first trying the antibactrial drugs to kill h-pylori which causes stomach acid and ulcer, the biggest scandal in medical history). Hence, would MYL see a growth while many physicians are prescribing antibacterial drugs? Only 20-25% of cases of stomach acidity may be linked to other factors than h-pylori bacteria.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next